Cellipont Bioservices Appoints Brett Reynolds as Chief Financial Officer to Lead Financial Strategy and Support Growth in Cell Therapy CDMO Sector

Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), today announced the appointment of Brett Reynolds as its new Chief Financial Officer, effective immediately. Mr. Reynolds has over 25 years of experience in financial leadership roles, primarily in the life sciences industry, and succeeds Tim Heher, who recently retired from the Company.

Cellipont Bioservices and Secretome Therapeutics Partner for cGMP Manufacturing for Master Cell Bank for Lead Asset STM-01

The Woodlands and Dallas, Texas, January 22, 2025/ Cision / – Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Secretome Therapeutics, a biotechnology company advancing therapies derived from neonatal cardiac progenitor cells (nCPCs), today announced a partnership for cGMP manufacturing of Secretome Therapeutic’s lead asset STM-01. Under this partnership, Cellipont

ADVA Biotechnology and Cellipont Bioservices Showcase Accelerated Transition from R&D to GMP at Advanced Therapies Week 2025

BARLEV, ISRAEL, AND THE WOODLANDS, TEXAS — JANUARY 12, 2025 — ADVA Biotechnology and Cellipont Bioservices are proud to announce their participation at Advanced Therapies Week 2025, taking place in Dallas, Texas, from January 20–23, 2025. Together, they will present a showcase study highlighting how their collaboration successfully transitioned a CAR-T process from a complex manual

Cellipont Bioservices and Xiogenix Announce Strategic Partnership to Enhance Client Access to Advanced Filling Systems

The Woodlands, Texas and Muskego, Wisconsin, December 10, 2024/ Cision / – Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Xiogenix, an innovator in biopharmaceutical technology, are pleased to announce a strategic partnership. This collaboration enables Cellipont Bioservices to offer its clients access to the state-of-the-art Ares™ X20 fill and

Cellipont Bioservices and Mongoose Bio Sign Agreement to Advance MGB-001, its Lead TCR-T therapy, towards the Clinic for Multiple Cancers

The Woodlands and Houston, Texas, October 8, 2024/ Cision / – Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Mongoose Bio, a private clinical-stage biopharmaceutical company pioneering next generation precision T-cell based therapies targeting solid cancers, today announced the signing of an agreement for the Technology Transfer, Process Development, and

Cellipont Bioservices Announces Darren Head As Chief Executive Officer & Minority Growth Equity Investment From HealthQuest Capital 

The Woodlands, TX, October 7, 2024 – Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), today announced Darren Head as Chief Executive Officer. In addition to his role as Chairman of the Board, Mr. Head brings deep institutional knowledge and a wealth of biopharmaceutical leadership experience to the role. This strategic